Innate Pharma (NASDAQ:IPHA) Stock Rating Lowered by HC Wainwright

Key Points

• HC Wainwright has reaffirmed its neutral rating for Innate Pharma with little change to their outlook.
• Leerink Partners has downgraded its price target for the stock to $2.00, down from $10.00, indicating a market perform rating.
• Innate Pharma's stock price is currently around $2.05 with a 52-week low of $1.29 and high of $3.51.

HC Wainwright lowered shares of Innate Pharma (NASDAQ:IPHA - Free Report) from a buy rating to a neutral rating in a research note published on Thursday, Marketbeat Ratings reports.

Other analysts also recently issued reports about the company. Leerink Partners restated a "market perform" rating and set a $2.00 price objective (down from $10.00) on shares of Innate Pharma in a research report on Thursday. BTIG Research initiated coverage on Innate Pharma in a research note on Monday, July 28th. They set a "buy" rating for the company. One research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Innate Pharma presently has a consensus rating of "Hold" and a consensus price target of $6.50.

Innate Pharma Stock Performance

NASDAQ IPHA traded down $0.05 during trading on Thursday, hitting $1.83. The stock had a trading volume of 10,882 shares, compared to its average volume of 93,469. The company's 50-day moving average price is $2.06 and its two-hundred day moving average price is $2.02. The company has a current ratio of 2.21, a quick ratio of 2.60 and a debt-to-equity ratio of 3.52. Innate Pharma has a 12 month low of $1.29 and a 12 month high of $3.51.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.